NXTM Financial Facts

Research and development: 6.75M
Cost of revenues: 51.8M
See Full Income Statement

Additional paid-in capital: 606.78M
Accrued expenses: 26.35M
See Full Balance Sheet

Nxstage Medical, Inc. (NXTM) Earnings

  |   Expand Research on NXTM
Next EPS Date 5/5/16 *Est. EPS Growth Rate +100.0% *Last Qtr.
Average EPS % Beat Rate +30.2% Revenue Growth Rate -100.0% *Last Qtr.
Average % Move 1-Wk after EPS +6.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/10/16 Q415 N/A-$0.04 N/A N/A$86.83M = N/A N/A
11/3/15 Q315 -$0.03-$0.08 +$0.05$86.5M$82.06M = Details
8/6/15 Q215 -$0.08-$0.10 +$0.02$80.3M$79.89M Details
5/6/15 Q115 -$0.09-$0.11 +$0.02$79.5M$77.92M Details
2/26/15 Q414 -$0.08-$0.10 +$0.02$79.9M$75.75M Details
9/30/14 Q314 N/A-$0.13 N/A N/A$71.72M N/A N/A
8/7/14 Q214 -$0.12-$0.11 -$0.01$74.1M$70.52M Details
5/8/14 Q114 -$0.09-$0.11 +$0.02$72.2M$69.44M Details